Preclinical characterization of JAK1/JAK2 inhibitors for treatment of type 1 diabetes

被引：0
|
作者：
Scott, N. A. [1 ,2 ]
Trivedi, P. M. [1 ,2 ]
Graham, K. L. [1 ,2 ]
Fynch, S. [1 ]
Jenkins, M. R. [3 ]
Kay, T. W. [1 ,2 ]
Thomas, H. E. [1 ,2 ]
机构：
[1] St Vincents Inst, Immunol & Diabet Unit, Fitzroy, Vic, Australia
[2] Univ Melbourne, St Vincents Hosp, Dept Med, Fitzroy, Vic, Australia
[3] Peter MacCallum Canc Ctr, Canc Immunol Res, East Melbourne, Australia
来源：
EUROPEAN JOURNAL OF IMMUNOLOGY | 2016年 / 46卷
关键词：
D O I：
暂无
中图分类号：
R392 [医学免疫学]; Q939.91 [免疫学];
学科分类号：
100102 ;
摘要：
3795
引用
收藏
页码：361 / 361
页数：1
相关论文
共 50 条
  • [1] Preclinical characterization of INCB028050, JAK1/JAK2 selective clinical candidate
    Fridman, Jordan
    Scherle, Peggy
    Collins, Robert
    Bum, Timothy
    Li, Yanlong
    Li, Jun
    Covington, Maryanne
    Thomas, Beth
    Favata, Margaret
    Shi, Jack
    Mcgee, Ryan
    Shepard, Stacey
    Rodgers, James
    Yeleswaram, Swamy
    Hollis, Greg
    Newton, Robert
    Metcalf, Brian
    Friedman, Steven
    Vaddi, Kris
    ARTHRITIS AND RHEUMATISM, 2008, 58 (09): : S296 - S297
  • [2] Preclinical Evaluation of Local JAK1 and JAK2 Inhibition in Cutaneous Inflammation
    Fridman, Jordan S.
    Scherle, Peggy A.
    Collins, Robert
    Burn, Timothy
    Neilan, Claire L.
    Hertel, Denise
    Contel, Nancy
    Haley, Patrick
    Thomas, Beth
    Shi, Jack
    Collier, Paul
    Rodgers, James D.
    Shepard, Stacey
    Metcalf, Brian
    Hollis, Gregory
    Newton, Robert C.
    Yeleswaram, Swamy
    Friedman, Steven M.
    Vaddi, Kris
    JOURNAL OF INVESTIGATIVE DERMATOLOGY, 2011, 131 (09) : 1838 - 1844
  • [3] Prevention of Islet Inflammatory Stress with JAK1/JAK2 Inhibitors
    Watson, Eleanor
    Waibel, Michaela
    Trivedi, Prerak
    Pappas, Evan
    Fynch, Stacey
    Sutherland, Robyn
    Kay, Thomas
    Thomas, Helen
    TRANSPLANTATION, 2018, 102 : S370 - S370
  • [4] Ruxolitinib, an oral JAK1 and JAK2 inhibitor, in myelofibrosis
    Vaddi, Kris
    Sarlis, Nicholas J.
    Gupta, Vikas
    EXPERT OPINION ON PHARMACOTHERAPY, 2012, 13 (16) : 2397 - 2407
  • [5] Selective Inhibition of JAK1 and JAK2 Is Efficacious in Rodent Models of Arthritis: Preclinical Characterization of INCB028050
    Fridman, Jordan S.
    Scherle, Peggy A.
    Collins, Robert
    Burn, Timothy C.
    Li, Yanlong
    Li, Jun
    Covington, Maryanne B.
    Thomas, Beth
    Collier, Paul
    Favata, Margaret F.
    Wen, Xiaoming
    Shi, Jack
    McGee, Ryan
    Haley, Patrick J.
    Shepard, Stacey
    Rodgers, James D.
    Yeleswaram, Swamy
    Hollis, Greg
    Newton, Robert C.
    Metcalf, Brian
    Friedman, Steven M.
    Vaddi, Kris
    JOURNAL OF IMMUNOLOGY, 2010, 184 (09): : 5298 - 5307
  • [6] MOMELOTINIB HYDROCHLORIDE JAK1/JAK2 inhibitor Treatment of myelofibrosis Treatment of pancreatic cancer
    Price, S.
    George, T.
    Pinilla-Ibarz, J.
    DRUGS OF THE FUTURE, 2015, 40 (09) : 561 - 568
  • [7] JAK1/JAK2 degraders based on PROTAC for topical treatment of atopic dermatitis
    Wu, Junchao
    Li, Lisha
    Zhu, Quangang
    Zhang, Tingrui
    Miao, Fengze
    Cui, Zhen
    Dong, Guoqiang
    Tai, Zongguang
    Chen, Zhongjian
    BIOMEDICINE & PHARMACOTHERAPY, 2024, 171
  • [8] Ruxolitinib, a selective JAK1 and JAK2 inhibitor for the treatment of myeloproliferative neoplasms and psoriasis
    Mesa, Ruben A.
    IDRUGS, 2010, 13 (06) : 394 - 403
  • [9] JAK1 selective inhibitors for the treatment of spondyloarthropathies
    White, Jonathan P. E.
    Coates, Laura C.
    RHEUMATOLOGY, 2021, 60 : II39 - II44
  • [10] JAK1 selective inhibitors for the treatment of spondyloarthropathies
    White, Jonathan P. E.
    Coates, Laura C.
    RHEUMATOLOGY, 2021, 60 (SUPPL 2) : ii39 - ii44
12345